Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
BURLINGTON, Mass., March 02, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its fiscal year 2016 financial results on Thursday, March 9, 2017, at 4:30 p.m. ET.
The dial-in number for the conference call is (855) 770-0022 for domestic participants and (908) 982-4677 for international participants, with Conference ID # 77592180. A live webcast of the conference call can also be accessed through the “Investors” tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA of the knee. The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contacts: Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected] Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected] Investor Contact: David Carey Lazar Partners LTD T: 212-867-1768 [email protected]
